HHS earmarks $884M for swine flu vaccines

The Department of Health and Human Services will hand out $884 million in funding to buy more ingredients an antigen and an adjuvant for swine flu vaccines. This is in addition to the $1 billion HHS committed to fighting the disease in May.

Novartis will get the bulk of the $884 million. The drugmaker has landed $690.1 million to produce bulk vaccine antigen as well as other ingredients. GlaxoSmithKline is being furnished with $71.4 million for bulk oil and water adjuvant, while Sanofi Pasteur will receive $61.4 million to produce ingredients.

MedImmune will use the technology from its FluMist nasal spray to develop a similar product for the treatment of swine flu, or H1N1. And the U.S. Government is giving the AstraZeneca subsidiary $61 million to fun development of the drug. The contract comes in addition to the $90 million in funding MedImmune received to make the ingredients for an H1N1 vaccine.

- here's the BizJournal report
- read the AP article

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.